What is the dosing for Cagrisema (Somatuline)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Cagrisema dosing is not directly addressed in the provided evidence, however, somatropin dosing is discussed in several studies, with a typical dose of 0.24 mg/kg/week for daily injections 1. Given the lack of direct information on Cagrisema, it's essential to consider the context of growth hormone deficiency treatment, where somatropin is commonly used.

  • The dosing of somatropin can vary based on the patient's condition, age, and response to treatment.
  • A study from 2022 compared the efficacy and safety of once-weekly somatrogon with once-daily somatropin in prepubertal children with growth hormone deficiency, with somatrogon dosed at 0.66 mg/kg/week 1.
  • Another study discussed the use of Norditropin (somatropin) in growth hormone deficiency, highlighting the importance of daily injections and the potential for adverse reactions such as intracranial hypertension and glucose intolerance 2.
  • The goal of growth hormone therapy is to promote linear growth, restore normal body composition, and improve cardiac function, with treatment outcomes depending on factors such as dose, duration, and individual patient response 3, 2, 4. It's crucial to consult the most recent and highest-quality studies for specific dosing recommendations, as well as to consider individual patient needs and potential side effects when determining the optimal treatment approach.
  • In clinical practice, the dosing of somatropin or similar growth hormone therapies should be tailored to the individual patient, taking into account their specific condition, age, and response to treatment, to minimize adverse effects and maximize treatment outcomes.

References

Research

Exercise capacity and hormonal response in adults with childhood onset growth hormone deficiency during long-term somatropin treatment.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.